Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion.
- DOI
- 10.1007/s00395-026-01177-6
- Published
- 2026 Jun
- Container
- Basic research in cardiology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00395-026-01177-6,
title = {Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion.},
author = {Rocca C and De Bartolo A and Granieri MC and Rago V and Conforti F and Urlandini L and Romeo N and Mattii L and De Caterina R and Pagliaro P and Angelone T and Penna C and Madonna R},
year = {2026},
journal = {Basic research in cardiology},
doi = {10.1007/s00395-026-01177-6},
url = {https://doi.org/10.1007/s00395-026-01177-6}
}RIS
TY - JOUR TI - Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion. AU - Rocca C AU - De Bartolo A AU - Granieri MC AU - Rago V AU - Conforti F AU - Urlandini L AU - Romeo N AU - Mattii L AU - De Caterina R AU - Pagliaro P AU - Angelone T AU - Penna C AU - Madonna R PY - 2026 JO - Basic research in cardiology DO - 10.1007/s00395-026-01177-6 UR - https://doi.org/10.1007/s00395-026-01177-6 ER -
APA
C, R., A, D. B., MC, G., V, R., F, C., L, U., N, R., L, M., R, D. C., P, P., T, A., C, P., & R, M. (2026). Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion.. Basic research in cardiology. https://doi.org/10.1007/s00395-026-01177-6
Source records
- pubmed · retrieved 2026-09-26T06:27:26.526Z